NCT00892489View on ClinicalTrials.gov

A Bioequivalence Study of 15 mg ER OROS Paliperidone

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

December 31, 2004

Conditions
Schizophrenia
Interventions
DRUG

ER OROS Paliperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00892489 - A Bioequivalence Study of 15 mg ER OROS Paliperidone | Biotech Hunter | Biotech Hunter